参考文献/References:
[1] Birch J,Gil J. Senescence and the SASP:many therapeutic avenues[J]. Genes Dev,2020,34(23-24):1565-1576.
[2] Hasan H,Park S,Auger C,et al. Thrombin induces angiotensin Ⅱ-mediated senescence in atrial endothelial cells:impact on pro-remodeling patterns[J]. J Clin Med,2019,8(10):1570.
[3] Shimizu I,Minamino T. Cellular senescence in cardiac diseases[J]. J Cardiol,2019,74(4):313-319.
[4] Guerrero A,Herranz N,Sun B,et al. Cardiac glycosides are broad-spectrum senolytics[J]. Nat Metab,2019,1(11):1074-1088.
[5] Shan H,Li T,Zhang L,et al. Heme oxygenase-1 prevents heart against myocardial infarction by attenuating ischemic injury-induced cardiomyocytes senescence[J]. EBioMedicine,2019,39:59-68.
[6] Kirkland JL,Tchkonia T. Cellular senescence: a translational perspective[J]. EBioMedicine,2017,21:21-28.
[7] Nikolich-Zugich J. The twilight of immunity:emerging concepts in aging of the immune system[J]. Nat Immunol,2018,19(1):10-19.
[8] Carreno G,Guiho R,Martinez-Barbera JP. Cell senescence in neuropathology:a focus on neurodegeneration and tumours[J]. Neuropathol Appl Neurobiol,2021,47(3):359-378.
[9] Boriani G. Atrial fibrillation and aging:risky mutual relationships[J]. Chest,2016,149(2):301-302.
[10] Kornej J,B?rschel CS,Benjamin EJ,et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights[J]. Circ Res,2020,127(1):4-20.
[11] Lin Y,Chen Y,Lee T,et al. Aging modulates the substrate and triggers remodeling in atrial fibrillation[J]. Circ J ,2018,82(5):1237-1244.
[12] Chen MS,Lee RT,Garbern JC. Senescence mechanisms and targets in the heart[J]. Cardiovasc Res,2022,118(5):1173-1187.
[13] Li YD,Hong YF,Zhang Y,et al. Association between reversal in the expression of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel and age-related atrial fibrillation[J]. Med Sci Monit,2014,20:2292-2297.
[14] Dun W,Yagi T,Rosen MR,et al. Calcium and potassium currents in cells from adult and aged canine right atria[J]. Cardiovasc Res,2003,58(3):526-534.
[15] Liu T,Xiong F,Qi XY,et al. Altered calcium handling produces reentry-promoting action potential alternans in atrial fibrillation-remodeled hearts[J]. JCI Insight,2020,5(8):e133754.
[16] North BJ,Sinclair DA. The intersection between aging and cardiovascular disease[J]. Circ Res,2012,110(8):1097-1108.
[17] Ihara K,Sasano T. Role of inflammation in the pathogenesis of atrial fibrillation [J]. Front Physiol,2022,13:862164.
[18] Lai LP,Tsai CC,Su MJ,et al. Atrial fibrillation is associated with accumulation of aging-related common type mitochondrial DNA deletion mutation in human atrial tissue[J]. Chest,2003,123(2):539-544.
[19] Lenski M,Schleider G,Kohlhaas M,et al. Arrhythmia causes lipid accumulation and reduced glucose uptake[J]. Basic Res Cardiol ,2015,110(4):40.
[20] Adili A,Zhu X,Cao H,et al. Atrial fibrillation underlies cardiomyocyte senescence and contributes to deleterious atrial remodeling during disease progression[J]. Aging Dis,2022,13(1):298-312.
[21] Mu?oz-Espín D,Serrano M. Cellular senescence:from physiology to pathology[J]. Nat Rev Mol Cell Biol,2014,15(7):482-496.
[22] Alejandra G,van Wagoner DR. Oxidant and inflammatory mechanisms and targeted therapy in AF:an update[J]. J Cardiovasc Pharmacol,2015,66(6):523-529.
[23] Jesel L,Abbas M,Park S,et al. Atrial Fibrillation progression is associated with cell senescence burden as determined by p53 and p16 expression[J]. J Clin Med,2020,9(1):36.
[24] Bussian TJ,Aziz A,Meyer CF,et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline[J]. Nature,2018,562(7728):578-582.
[25] Walaszczyk A,Dookun E,Redgrave R,et al. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction[J]. Aging Cell,2019,18(3):e12945.
[26] Mu?oz Espín D,Rovira M,Galiana I,et al. A versatile drug delivery system targeting senescent cells[J]. EMBO Mol Med,2018,10(9):e9355.
[27] López-Otín C,Blasco MA,Partridge L,et al. The hallmarks of aging[J]. Cell,2013,153(6):1194-1217.
[28] Wang Y,Su?ac L,Feigon J. Structural biology of telomerase[J]. Cold Spring Harb Perspect Biol,2019,11(12):a032383.
[29] Jaskelioff M,Muller FL,Paik JH,et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice[J]. Nature,2011,469(7328):102-106.
[30] Méndez-Pertuz M,Martínez P,Blanco-Aparicio C,et al. Modulation of telomere protection by the PI3K/AKT pathway[J]. Nat Commun,2017,8(1):1278.
[31] Mojiri A,Walther BK,Jiang C,et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice[J]. Eur Heart J,2021,42(42):4352-4369.
[32] Meng X,Nikolic-Paterson DJ,Lan HY. TGF-β:the master regulator of fibrosis[J]. Nat Rev Nephrol,2016,12(6):325-338.
[33] Sohns C,Marrouche NF. Atrial fibrillation and cardiac fibrosis[J]. Eur Heart J,2020,41(10):1123-1131.
[34] Hu HH,Chen DQ,Wang YN,et al. New insights into TGF-β/Smad signaling in tissue fibrosis[J]. Chem Biol Interact,2018,292:76-83.
[35] Budi EH,Schaub JR,Decaris M,et al. TGF‐β as a driver of fibrosis:physiological roles and therapeutic opportunities[J]. J Pathol,2021,254(4):358-373.
[36] Wu Y,Can J,Hao S,et al. LOXL2 inhibitor attenuates angiotensin ii-induced atrial fibrosis and vulnerability to atrial fibrillation through inhibition of transforming growth factor beta-1 Smad2/3 pathway[J]. Cerebrovasc Dis,2022,51(2):188-198.
[37] Ruwanpura SM,Thomas BJ,Bardin PG. Pirfenidone:molecular mechanisms and potential clinical applications in lung disease[J]. Am J Respir Cell Mol Biol,2020,62(4):413-422.
[38] Lee KW,Everett TH 4th,Rahmutula D,et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure[J]. Circulation,2006,114(16):1703-1712.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(12):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(12):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(12):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(12):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(12):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]